๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab (AC-TH) produce superior disease-free survival (DFS) compared to AC-T in patients (pts) with HER-2 positive early breast cancer (EBC), with increased cardiac toxicity confined to AC-TH: BCIRG 006 study

โœ Scribed by J. Crown; Eiermann; N. Robert; T. Pienkowski; M. Martin; M. Pawlicki; A. Chan; M. Smylie; M. Pegram; D. Slamon

Book ID
118624510
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
142 KB
Volume
4
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Cardiac safety analysis of the first sta
Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)
โœ C Geyer; J Bryant; E Romond; E Tan-Chiu; M Ewer; D Keefe; R Shannon; G Yothers; ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 541 KB